secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001213900-24-002430
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital shareholders approve merger with Longevity Biomedical; 4.44M shares redeemed
--------------------------------------------------------------------------------

- Shareholders approved all proposals: Business Combination, Merger, Share Capital, Organizational Documents, Governance, and Incentive Plan.
- Approximately 4,440,202 public shares redeemed from trust account after withdrawals, ahead of closing.
- Adjornment proposal not needed as sufficient votes secured for all other proposals.
- Company plans to close the Business Combination as detailed in the proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024002430/0001213900-24-002430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024002430/ea191397-8k_denalicap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-002430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer